Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma | MicrobiomeTrials← Back to trialsNCT06141031
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-01-16Est. Completion: 2029-06-30
Enrollment target: 24 participants Locations- University of Colorado, Aurora, Colorado, United States
- Washington University School of Medicine, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Oesophageal Squamous Cell CarcinomaOesophageal AdenocarcinomaGastric AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)Colorectal Adenocarcinoma
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlie…
Maidstone, United KingdomEst. completion Feb 2, 2028
Pancreatic Cancer
This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderl…
Multiple LocationsEst. completion Dec 31, 2029
Neuroendocrine TumorsCarcinoid Tumor
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from t…
Aarau, SwitzerlandCompleted Aug 31, 2025